NCT07335185Not yet recruiting
Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 3000 (estimated)
- First submitted
- 5 Jan 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Oct 2030
- Lead sponsor
- Gravity Medical Technology, INC
- Diseases
- Stroke
- NCT number
- NCT07335185
What you commit to
- Study type: Interventional
- Planned participants: 3000
- From 1 Jan 2026 to the primary completion date, 31 Oct 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm where the study procedure or treatment might confound the results of the registry.
Who the study is looking for
- Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral artery.
- Subject has been or will be treated with Supernova and/or Neutron devices as the initial device used to remove the thrombus
- Subject is willing to participate in a 90-day follow-up visit.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.